MedTrace Logo

Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin

NCT03671538 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2018-09-17

No results posted yet for this study

Summary

Chemotherapy is still the standard first-line treatment option for EGFR unmutated patients. After a randomized phase Ⅲ trial, BEYOND was presented the synergistic effect of progression-free survival(PFS) could be expected when chemotherapy is combined with Antiangiogenesis agent bevacizumab in China;Therefore,in this study, The investigators will investigate the efficacy and safety of Anlotinb combined With Pemetrexed and Cisplatin as first-line therapy in patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations.

Conditions

  • Non-squamous Non-small Cell Lung Cancer

Interventions

DRUG

Anlotinib

Anlotinib 12mg qd on day 1 to 14 of a 21-day cycle

DRUG

pemetrexed

pemetrexed 500mg/m2 on day 1 of a 21-day cycle ;

DRUG

Cisplatin

Cisplatin 75mg/m2 on day 1 of a 21-day cycle ;

Sponsors & Collaborators

  • Lingyu Luo

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2019-08-31
Completion
2020-08-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03671538 on ClinicalTrials.gov